WO2008152448A3 - Streptococcus proteins, and their use in vaccination - Google Patents

Streptococcus proteins, and their use in vaccination Download PDF

Info

Publication number
WO2008152448A3
WO2008152448A3 PCT/IB2007/004637 IB2007004637W WO2008152448A3 WO 2008152448 A3 WO2008152448 A3 WO 2008152448A3 IB 2007004637 W IB2007004637 W IB 2007004637W WO 2008152448 A3 WO2008152448 A3 WO 2008152448A3
Authority
WO
WIPO (PCT)
Prior art keywords
pho3
pho1
present
pho2
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2007/004637
Other languages
French (fr)
Other versions
WO2008152448A2 (en
Inventor
Steven Neville Chatfield
Mark Redfern
Helen Harries
Joanne Bedwell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Emergent Product Development UK Ltd
Original Assignee
Emergent Product Development UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Emergent Product Development UK Ltd filed Critical Emergent Product Development UK Ltd
Priority to EP07874553A priority Critical patent/EP2104512A2/en
Publication of WO2008152448A2 publication Critical patent/WO2008152448A2/en
Publication of WO2008152448A3 publication Critical patent/WO2008152448A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/09—Lichens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/56944—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The present invention is directed to providing a vaccine to enhance the immune response of an animal in need of protection against a Group B Streptococcus (GBS) infection. The present invention is also directed toward a composition comprising two or more of polypeptides, wherein said polypeptide comprises an amino acid sequence at least 80% identical to the reference amino acid sequence selected from the group consisting of Pho1-13, Pho1-14, Pho1-5, Pho3-3 (pho1-7), Pho2-10, Pho2-15, Pho2-2 (ME:P22), Pho3-14, Pho3-17, Pho3-18, Pho3-1 (ME:P31), Pho3-21, Pho3-22, Pho3-23, Pho3-24, Pho3- 29, Pho3-50, MS4, MS11, MS16, MS14, MS10(NP GAP, ME:NAP), PBP, pho 3-9, OCT, PGK, and NPGAP, a fragment, variant, analog, or derivative thereof, wherein said polypeptide is recognizable by an antibody preparation that specifically binds to a polypeptide consisting of the reference amino acid sequence. In some embodiments, the present invention is directed to a method of inducing an immune response in a host comprising administering to said host an effective amount of the composition of the present invention.
PCT/IB2007/004637 2006-12-21 2007-12-21 Streptococcus proteins, and their use in vaccination Ceased WO2008152448A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP07874553A EP2104512A2 (en) 2006-12-21 2007-12-21 Streptococcus proteins, and their use in vaccination

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US87615606P 2006-12-21 2006-12-21
US60/876,156 2006-12-21
US98511107P 2007-11-02 2007-11-02
US60/985,111 2007-11-02

Publications (2)

Publication Number Publication Date
WO2008152448A2 WO2008152448A2 (en) 2008-12-18
WO2008152448A3 true WO2008152448A3 (en) 2009-05-22

Family

ID=40130254

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2007/004637 Ceased WO2008152448A2 (en) 2006-12-21 2007-12-21 Streptococcus proteins, and their use in vaccination

Country Status (2)

Country Link
EP (1) EP2104512A2 (en)
WO (1) WO2008152448A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102695523A (en) 2009-09-10 2012-09-26 诺华有限公司 Combination vaccines against respiratory tract diseases
WO2011048041A1 (en) * 2009-10-19 2011-04-28 Intervet International B.V. Streptococcal combi-vaccine
RU2632651C2 (en) * 2011-05-11 2017-10-06 Чилдрен'С Медикал Сентер Корпорейшн Modified biotin-binding protein, fusion proteins based thereon and their application
EP4272750A3 (en) 2013-02-07 2024-01-24 Children's Medical Center, Corp. Protein antigens that provide protection against pneumococcal colonization and/or disease
EP3600400A4 (en) 2017-03-28 2021-01-13 The Children's Medical Center Corporation MULTIPLE ANTIGEN PRESENTATION SYSTEM (MAPS) BASED STAPHYLOCOCCUS AUREUS VACCINE, IMMUNOGEN COMPOSITION AND THEIR USES
SG11201912601RA (en) 2017-06-23 2020-01-30 Nosocomial Vaccine Corp Immunogenic compositions
CN112969474A (en) 2018-09-12 2021-06-15 艾芬尼维克斯公司 Multivalent pneumococcal vaccine
CN113164580B (en) 2018-09-12 2025-06-10 儿童医疗中心公司 Pneumococcal fusion protein vaccine
MX2024002779A (en) 2021-09-09 2024-06-11 Affinivax Inc Multivalent pneumococcal vaccines.

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000037646A2 (en) * 1998-12-22 2000-06-29 Microscience Limited Group b streptococcus proteins, and their use
WO2000037490A2 (en) * 1998-12-22 2000-06-29 Microscience Limited Outer surface proteins, their genes, and their use
WO2002072623A1 (en) * 2001-03-09 2002-09-19 Microscience Limited Genes and proteins, and their use
WO2005028618A2 (en) * 2003-09-15 2005-03-31 Chiron Corporation Immunogenic compositions for streptococcus agalactiae

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000037646A2 (en) * 1998-12-22 2000-06-29 Microscience Limited Group b streptococcus proteins, and their use
WO2000037490A2 (en) * 1998-12-22 2000-06-29 Microscience Limited Outer surface proteins, their genes, and their use
WO2002072623A1 (en) * 2001-03-09 2002-09-19 Microscience Limited Genes and proteins, and their use
WO2005028618A2 (en) * 2003-09-15 2005-03-31 Chiron Corporation Immunogenic compositions for streptococcus agalactiae

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MARTIN J.G. HUGHES ET AL.: "Novel protein vaccine candidates against Group B streptococcal infection identified using alkaline phosphatase fusions", FEMS MICROBIOLOGY LETTERS, vol. 222, 2003, pages 263 - 271, XP002514097 *

Also Published As

Publication number Publication date
EP2104512A2 (en) 2009-09-30
WO2008152448A2 (en) 2008-12-18

Similar Documents

Publication Publication Date Title
Mbawuike et al. Mucosal immunity to influenza without IgA: an IgA knockout mouse model
McNeela et al. A mucosal vaccine against diphtheria: formulation of cross reacting material (CRM197) of diphtheria toxin with chitosan enhances local and systemic antibody and Th2 responses following nasal delivery
Sambhara et al. Heterosubtypic Immunity against Human Influenza A Viruses, Including Recently Emerged Avian H5 and H9 Viruses, Induced by FLU–ISCOM Vaccine in Mice Requires both Cytotoxic T-Lymphocyte and Macrophage Function
JP2015500827A5 (en)
Nussbaum et al. Involvement of Toll-like receptors 2 and 4 in the innate immune response to Treponema denticola and its outer sheath components
JP2012523246A5 (en)
JP2012504660A5 (en)
JP2004535187A (en) Mutant forms of cholera holotoxin as adjuvants
Novotny et al. Kinetic analysis and evaluation of the mechanisms involved in the resolution of experimental nontypeable Haemophilus influenzae-induced otitis media after transcutaneous immunization
Abkar et al. Survey of Omp19 immunogenicity against Brucella abortus and Brucella melitensis: influence of nanoparticulation versus traditional immunization
Jones et al. Protollin™: a novel adjuvant for intranasal vaccines
CA2739581A1 (en) Compositions and methods related to bacterial eap, emp, and/or adsa proteins
NO20004972D0 (en) Derivatives of pneumococcal choline binding proteins
JP2012501959A5 (en)
Naito et al. The protective effects of nasal PcrV‐CpG oligonucleotide vaccination against Pseudomonas aeruginosa pneumonia
Cheong et al. Epigallocatechin-3-gallate as a novel vaccine adjuvant
Michalek et al. A vaccine against dental caries: an overview
JP2015529677A5 (en)
JP5661744B2 (en) Polypeptides from enterococci and their use for vaccination
Mifsud et al. Reducing the impact of influenza‐associated secondary pneumococcal infections
Verma et al. A recombinant trivalent fusion protein F1–LcrV–HSP70 (II) augments humoral and cellular immune responses and imparts full protection against Yersinia pestis
JP2015513314A5 (en)
NZ601980A (en) Recombinant proteins for use in vaccine, antibodies against said proteins, and diagnostic and therapeutic methods including the same
JP6541158B2 (en) Mucosal vaccine adjuvant
Khan et al. Respiratory syncytial virus F and G protein core fragments fused to HBsAg-binding protein (SBP) induce a Th1-dominant immune response without vaccine-enhanced disease

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07874553

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2007874553

Country of ref document: EP